<DOC>
	<DOCNO>NCT00722839</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build immune response kill cytomegalovirus . PURPOSE : This phase I trial study side effect best dose vaccine therapy prevent cytomegalovirus healthy participant .</brief_summary>
	<brief_title>Vaccine Therapy Preventing Cytomegalovirus Healthy Participants</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish whether 3 vaccine dose level PADRE-CMV tetanus-CMV fusion peptide vaccine safe well tolerate healthy cytomegalovirus ( CMV ) -seropositive -seronegative participant . - To establish safe dose level PADRE-CMV tetanus-CMV fusion peptide vaccine combination PF 03512676 DNA participant . Secondary - To provide preliminary evidence enhance cellular immunity CMV level T cell would support potential feasibility cell transfer donor recipient hematopoietic stem cell transplantation ( HSCT ) amount consistent protection disease . - To determine whether reduce dose peptide vaccine immunogenic combination PF 03512676 DNA . - To confer CMV-specific cytotoxic T-lymphocyte ( CTL ) function CMV-negative participant . - To determine duration immune enhancement CMV-specific CTL function 12 month follow immunization healthy participant . OUTLINE : This dose-escalation study PADRE-CMV tetanus-CMV fusion peptide vaccine . Participants stratify accord cytomegalovirus ( CMV ) serum status ( positive v negative ) . Participants assign 1 2 group . - Group A : Participants receive either PADRE-CMV fusion peptide vaccine tetanus-CMV fusion peptide vaccine subcutaneously ( SC ) day 1 , 21 , 42 , 63 absence unacceptable toxicity . - Group B : Participants receive either PADRE-CMV fusion peptide vaccine CpG 7909 adjuvant SC tetanus-CMV fusion peptide vaccine CpG 7909 adjuvant SC day 1 , 21 , 42 , 63 absence unacceptable toxicity . Participants contact telephone every 3-7 day immunization . Participants also complete notebook health-related event 14 day immunization . Participants undergo blood sample collection baseline periodically study immunologic laboratory study , include flow cytometry , HLA-A2-CMV-tetramer , CMV-specific intracellular cytokine , CMV-specific CD107 degranulation , lymphoproliferation , chromium release assay . After completion study therapy , participant follow 1 year .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytomegalovirus ( CMV ) seropositivity seronegativity HLA A*0201 positive OR positive tetramerbinding use CMV peptide 495503 HLA A2 subtypes HLA A*0201 A2CMVTet cell ≤ 10^8/L PATIENT CHARACTERISTICS : Platelet count within 1.5 time upper level normal ( ULN ) The following blood chemistry study must normal : Sodium Potassium Chloride Carbon dioxide Glucose BUN Creatinine Uric acid WBC Hemoglobin Hematocrit The following study must ≤ ULN : Albumin Alkaline phosphatase AST ALT Lactic dehydrogenase Total bilirubin Hepatitis B virus surface antigen negative Hepatitis C virus seronegative No diagnosis associate immunodeficiency ( e.g. , HIV ) No active infection require treatment No know cardiac disease include hypertension and/or high cholesterol No serious abnormality EKG ( participant ≥ 50 year age ) Not pregnant Negative pregnancy test Fertile participant must use effective contraception study 6 week fourth last dose vaccine No history allergic reaction tetanus toxoid No history follow : Cancer basal cell carcinoma skin Depression Allergic diathesis , define history asthma Anaphylaxis Generalized urticaria daily use antihistamine Episodic ( past 3 month ) inhalational medication include steroidal agent Nonsteroidal agent cromolyn sodium Frequent migraine , define 3 episode past year No prior concurrent infectious condition PRIOR CONCURRENT THERAPY : More 6 month since prior participation CMV immunotherapy trial More 30 day since prior live vaccine More 2 week since prior inactivate vaccine No concurrent daily medication chronic current illness , except follow : Thyroidreplacement therapy Estrogenreplacement therapy Dietary vitamin protein supplement Any medication , determine principal investigator , know likely immunosuppressive No surgery past 6 month require general anesthesia Minor procedure ( e.g. , dental surgery superficial diagnostics biopsy ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>cytomegalovirus infection</keyword>
</DOC>